Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Elicio Therapeutics Inc (ELTX)

Elicio Therapeutics Inc (ELTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 194,078
  • Shares Outstanding, K 18,396
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,570 K
  • EBIT $ -38 M
  • EBITDA $ -36 M
  • 60-Month Beta 1.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 116.63

Options Overview Details

View History
  • Implied Volatility 303.89% (+3.86%)
  • Historical Volatility 92.38%
  • IV Percentile 59%
  • IV Rank 46.80%
  • IV High 576.32% on 11/20/25
  • IV Low 64.29% on 08/15/25
  • Expected Move (DTE 23) 4.89 (44.84%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 12
  • Volume Avg (30-Day) 168
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 5,171
  • Open Int (30-Day) 4,999
  • Expected Range 6.01 to 15.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.49
  • Number of Estimates 1
  • High Estimate -0.49
  • Low Estimate -0.49
  • Prior Year -0.87
  • Growth Rate Est. (year over year) +43.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.28 +7.88%
on 03/24/26
14.93 -25.72%
on 03/02/26
+0.11 (+1.00%)
since 02/25/26
3-Month
7.37 +50.47%
on 01/30/26
14.93 -25.72%
on 03/02/26
+2.90 (+35.41%)
since 12/24/25
52-Week
4.60 +141.09%
on 04/09/25
14.93 -25.72%
on 03/02/26
+2.78 (+33.45%)
since 03/25/25

Most Recent Stories

More News
Elicio Therapeutics Reports Inducement Grants

BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies...

ELTX : 11.07 (+4.93%)
Elicio Therapeutics: Q4 Earnings Snapshot

Elicio Therapeutics: Q4 Earnings Snapshot

ELTX : 11.07 (+4.93%)
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

Event-driven primary disease-free survival (“DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”) is anticipated in 1H 2026...

ELTX : 11.07 (+4.93%)
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies...

ELTX : 11.07 (+4.93%)
Elicio Therapeutics Reports Inducement Grants

BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies...

ELTX : 11.07 (+4.93%)
Elicio Therapeutics Reports Inducement Grants

BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies...

ELTX : 11.07 (+4.93%)
Elicio Therapeutics Reports Inducement Grants

BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies...

ELTX : 11.07 (+4.93%)
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy...

ELTX : 11.07 (+4.93%)
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies...

ELTX : 11.07 (+4.93%)
Elicio Therapeutics: Q3 Earnings Snapshot

Elicio Therapeutics: Q3 Earnings Snapshot

ELTX : 11.07 (+4.93%)

Business Summary

Elicio Therapeutics is a privately-held clinical-stage biotechnology company. It involved in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. Elicio Therapeutics, formerly known as Angion Biomedica Corp, is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 11.48
2nd Resistance Point 11.18
1st Resistance Point 10.87
Last Price 11.07
1st Support Level 10.26
2nd Support Level 9.96
3rd Support Level 9.65

See More

52-Week High 14.93
Last Price 11.07
Fibonacci 61.8% 10.98
Fibonacci 50% 9.77
Fibonacci 38.2% 8.55
52-Week Low 4.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.